UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study

Haematologica (Roma), 2020-09, Vol.105 (9), p.2308-2315

2020

Volltextzugriff (PDF)

Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients

International journal of hematology, 2020-11, Vol.112 (5), p.640-649

2020

Volltextzugriff (PDF)

Correction to: Patient’s age and D‑dimer levels predict the prognosis in patients with TAFRO syndrome

International journal of hematology, 2021-08, Vol.114 (2), p.301-302

2021

Volltextzugriff (PDF)

Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation

International journal of hematology, 2008-12, Vol.88 (5), p.588-595

2008

Volltextzugriff (PDF)

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of the Phase 3 Candor Study in Patients with Early or Late Relapse

Blood, 2020-11, Vol.136 (Supplement 1), p.37-38

2020

Volltextzugriff (PDF)

Case of Angioimmunoblastic T-cell Lymphoma Presenting as a Methotrexate-associated Lymphoproliferative Disorder with Extreme Peripheral Blood Plasmacytosis

Internal Medicine, 2022, pp.8422-21

2022

Volltextzugriff (PDF)

Elotuzumab Plus Pomalidomide/Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Japanese Subanalysis of the Randomized Phase 2 Eloquent-3 Study

Blood, 2018-11, Vol.132 (Supplement 1), p.3260-3260

2018

Volltextzugriff (PDF)

Treatment strategy in untreated transplant-eligible multiple myeloma patients

Rinshō ketsueki, 2016, Vol.57 (10), p.2064

Sunami, Kazutaka

2016

Volltextzugriff (PDF)

OPTIMISMM Japanese Subgroup Analysis: Pomalidomide, Bortezomib, and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2019-10, Vol.19 (10), p.e270-e271

2019

Volltextzugriff (PDF)

Safety and Efficacy of Elotuzumab with Lenalidomide/Dexamethasone for Multiple Myeloma in a Japanese Subpopulation Analysis of the Phase 3 Eloquent-2 Trial

Blood, 2016-12, Vol.128 (22), p.3315-3315

2016

Volltextzugriff (PDF)

Antileukemic

Nihon rinshō, 2015-02, Vol.73 Suppl 2, p.191

2015

Volltextzugriff (PDF)

Improved survival outcomes and relative youthfulness of multiple myeloma patients with t(4;14) receiving novel agents are associated with poorer performance of the revised international staging system in a real aging society

Oncotarget, 2019-01, Vol.10 (5), p.595-605

2019

Volltextzugriff (PDF)

Proposal of Progressive Adult Onset EBV-Associated Lymphoproliferative Disorder (PAEBV) as a Rapid-Onset Neoplastic Disease

Blood, 2009-11, Vol.114 (22), p.2920-2920

2009

Volltextzugriff (PDF)

Characteristics and Risk for Progression of Smoldering Multiple Myeloma: Japanese Nationwide Retrospective Survey

Annals of oncology, 2014-10, Vol.25, p.v60

2014

Volltextzugriff (PDF)

A Phase 1 Trial of OPB-111077 in Combination with Bendamustine (B) and Rituximab (R) in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of Dose-Escalation Stage

Blood, 2023-11, Vol.142 (Supplement 1), p.4464-4464

2023

Volltextzugriff (PDF)

MM-004: A Phase 1, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, Efficacy, and Pharmacokinetics of Pomalidomide Alone or in Combination with Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma in Japan

Blood, 2014-12, Vol.124 (21), p.2107-2107

2014

Volltextzugriff (PDF)

Subcutaneous Isatuximab Administration By an on-Body Delivery System (OBDS) in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1b Expansion Study Results

Blood, 2022-11, Vol.140 (Supplement 1), p.4412-4414

2022

Volltextzugriff (PDF)

Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort

Blood, 2022-11, Vol.140 (Supplement 1), p.4407-4408

2022

Volltextzugriff (PDF)

Subcutaneous (SC) isatuximab administration by an on-body delivery system (OBDS) in combination with pomalidomide-dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma (RRMM): Interim phase 1b study results

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.8025-8025

2022

Volltextzugriff (PDF)

CD79 Expression Is Associated with Cell-of-Origin and Outcome in Diffuse Large B-Cell Lymphoma

Blood, 2023-11, Vol.142 (Supplement 1), p.1760-1760

2023

Volltextzugriff (PDF)

Evaluation of the Revised International Staging System in 400 Patients with Symptomatic Myeloma in a Japanese Clinical Setting

Blood, 2018-11, Vol.132 (Supplement 1), p.4477-4477

2018

Volltextzugriff (PDF)

Clinical Impact of Cell-of-Origin and Double-Hit Signature of DLBCL in Japan

Blood, 2022-11, Vol.140 (Supplement 1), p.6421-6423

2022

Volltextzugriff (PDF)

1 – 25 von 89

Suche als RSS-Feed

Aktive Filter

ThemaMultiple Myeloma - Drug Therapy

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(78)
Mit Volltextzugriff
(76)

Publikationsform

Artikel
(89)

Sprache

Englisch
(81)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

Humans
(7)
Hematology
(5)
Oncology
(5)
Cardiovascular
(4)
Male
(3)
Myeloma
(3)
Adult
(2)
Bcr-Abl
(2)
Correction
(2)
Hbv
(2)
Hematopoietic Stem Cell Transplantation
(2)
Imatinib
(2)
Leukemia - Drug Therapy
(2)
Medicine
(2)
Medicine & Public Health
(2)
Middle Aged
(2)
Minimal Residual Disease
(2)
Multiple Myeloma
(2)
Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
(2)
Tyrosine Kinase Inhibitor
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study

Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients

Correction to: Patient’s age and D‑dimer levels predict the prognosis in patients with TAFRO syndrome

Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation

P929: CIRCULATING TUMOR DNA ASSESSMENT IMPROVES PROGNOSTIC PREDICTION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING IXAZOMIB, LENALIDOMIDE, AND DEXAMETHASONE

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of the Phase 3 Candor Study in Patients with Early or Late Relapse

Case of Angioimmunoblastic T-cell Lymphoma Presenting as a Methotrexate-associated Lymphoproliferative Disorder with Extreme Peripheral Blood Plasmacytosis

Elotuzumab Plus Pomalidomide/Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Japanese Subanalysis of the Randomized Phase 2 Eloquent-3 Study

Treatment strategy in untreated transplant-eligible multiple myeloma patients

OPTIMISMM Japanese Subgroup Analysis: Pomalidomide, Bortezomib, and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Safety and Efficacy of Elotuzumab with Lenalidomide/Dexamethasone for Multiple Myeloma in a Japanese Subpopulation Analysis of the Phase 3 Eloquent-2 Trial

Antileukemic

Improved survival outcomes and relative youthfulness of multiple myeloma patients with t(4;14) receiving novel agents are associated with poorer performance of the revised international staging system in a real aging society

Proposal of Progressive Adult Onset EBV-Associated Lymphoproliferative Disorder (PAEBV) as a Rapid-Onset Neoplastic Disease

Characteristics and Risk for Progression of Smoldering Multiple Myeloma: Japanese Nationwide Retrospective Survey

A Phase 1 Trial of OPB-111077 in Combination with Bendamustine (B) and Rituximab (R) in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of Dose-Escalation Stage

MM-004: A Phase 1, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, Efficacy, and Pharmacokinetics of Pomalidomide Alone or in Combination with Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma in Japan

Subcutaneous Isatuximab Administration By an on-Body Delivery System (OBDS) in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1b Expansion Study Results

Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort

ctDNA improves prognostic prediction in relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone

Subcutaneous (SC) isatuximab administration by an on-body delivery system (OBDS) in combination with pomalidomide-dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma (RRMM): Interim phase 1b study results

CD79 Expression Is Associated with Cell-of-Origin and Outcome in Diffuse Large B-Cell Lymphoma

Evaluation of the Revised International Staging System in 400 Patients with Symptomatic Myeloma in a Japanese Clinical Setting

Survival and CNS Relapse in Patients with CD5-Positive Diffuse Large B-Cell Lymphoma: A Multi-Institutional Observational Study in Japan

Clinical Impact of Cell-of-Origin and Double-Hit Signature of DLBCL in Japan

Aktive Filter

Suchergebnisse filtern